VIVIANE MAZO FAVERO GIMENES

(Fonte: Lattes)
Índice h a partir de 2011
8
Lattes
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/53 - Laboratório de Micologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Revista / Livro: Brazilian Journal of Medical and Biological Research ×

Resultados de Busca

Agora exibindo 1 - 1 de 1
  • article 17 Citação(ões) na Scopus
    Antifungal susceptibility profile of Candida clinical isolates from 22 hospitals of Sao Paulo State, Brazil
    (2021) RODRIGUES, D. K. B.; BONFIETTI, L. X.; GARCIA, R. A.; ARAUJO, M. R.; RODRIGUES, J. S.; GIMENES, V. M. F.; MELHEM, M. S. C.
    This study aimed to evaluate the frequency of cryptic Candida species from candidemia cases in 22 public hospitals in Sao Paulo State, Brazil, and their antifungal susceptibility profiles. During 2017 and 2018, 144 isolates were molecularly identified as 14 species; C. parapsilosis (32.6%), C. albicans (27.7%), C. tropicalis (14.6%), C. glabrata (9.7%), C. krusei (2.8%), C. orthopsilosis (2.8%), C. haemulonii var. vulnera (2.1%), C. haemulonii (1.4%), C. metapsilosis (1.4%), C. dubliniensis (1.4%), C. guilliermondii (1.4%), C. duobushaemulonii (0.7%), C. kefyr (0.7%), and C. pelliculosa (0.7%). Poor susceptibility to fluconazole was identified in 6.4% of C. parapsilosis isolates (0.12 to >64 mu g/mL), 50% of C. guilliermondii (64 mu g/mL), 66.6% of C. haemulonii var. vulnera (16-32 mu g/mL), and C. duobushaemulonii strain (MIC 64 mu g/mL). Our results corroborated the emergence of C. glabrata in Brazilian cases of candidemia as previously reported. Importantly, we observed a large proportion of non-wild type C. glabrata isolates to voriconazole (28.6%; <0.015 to 4 mu g/mL) all of which were also resistant to fluconazole (28.6%). Of note, C. haemulonii, a multidrug resistant species, has emerged in the Southeast region of Brazil. Our findings suggested a possible epidemiologic change in the region with an increase in fluconazole-resistant species causing candidemia. We stress the relevance of routine accurate identification to properly manage therapy and monitor epidemiologic trends.